Basal triple-negative breast cancer (TNBC) is a common form of human breast cancer for which there are no specific, targeted therapies, unlike hormone-responsive or Her2+ breast cancers. TNBC has a much worse prognosis than hormone receptor + cancer and is disproportionately high in the African-American population. NIH scientists have created and characterized a transgenic model that is currently an excellent mouse model for TNBC that shares important molecular characteristics of human TNBC, making it highly useful for preclinical testing of drugs and novel therapies. This model may provide a valuable means of identifying new drugs and therapies that could be translated to human clinical trials. The mouse model also develops prostate intraepithelial neoplasia and prostate cancer, therefore has also been used for studies of prostate cancer. The studies using the mouse model may fill important public health service needs.
CRADA Opportunity: The Transgenic Oncogenesis and Genomics Section of the Laboratory of Cancer Biology and Genetics, Center for Cancer Research, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this mouse model of TNBC to study cancer biology and for preclinical testing. Please contact John Hewes, Ph.D. at 301-435-3121 or
hewesj@mail.nih.gov for more information.
Click here to view the NCI collaborative opportunity announcement.
Source: http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=2131
Jenny McCarthy Jessica Alba Jessica Biel Jessica Cauffiel Jessica Par?
No comments:
Post a Comment